Furiex Pharmaceuticals, Inc. - FORM 10-K - EX-32.2 - CERTIFICATION BY THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 906 - March 7, 2012

Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - Furiex Pharmaceuticals, Inc.Financial_Report.xls
10-K - FORM 10-K - Furiex Pharmaceuticals, Inc.d276649d10k.htm
EX-32.1 - CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 906 - Furiex Pharmaceuticals, Inc.d276649dex321.htm
EX-23.1 - CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - Furiex Pharmaceuticals, Inc.d276649dex231.htm
EX-21.1 - SUBSIDIARIES OF FURIEX PHARMACEUTICALS, INC. - Furiex Pharmaceuticals, Inc.d276649dex211.htm
EX-31.1 - CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 - Furiex Pharmaceuticals, Inc.d276649dex311.htm
EX-31.2 - CERTIFICATION BY THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 302 - Furiex Pharmaceuticals, Inc.d276649dex312.htm

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Furiex Pharmaceuticals, Inc. (the “Company”) on Form 10-K for the period ended December 31, 2011 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Marshall H. Woodworth, Chief Financial Officer, Treasurer and Assistant Secretary (principal financial and accounting officer) of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, to my knowledge that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of, and for, the periods presented in the Report.

 

/s/ Marshall H. Woodworth
Marshall H. Woodworth
Chief Financial Officer, Treasurer and Assistant Secretary
(principal financial and accounting officer)

March 7, 2012

Furiex Pharmaceuticals, Inc. Reports

Also read